To provide a BAFF-R for therapeutic use with a glycosylation pattern that can be characterized unambiguously, and that avoids aggregation in eukaryotic cells while maintaining specificity and affinity for BAFF.
There is provided a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. There is also provided methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders. TNF-family ligands and receptors and antagonists and agonists thereof and their use in modulation of immune responses are related. The present invention is based, in part, on the discovery and characterization of the glycosylation pattern of human BAFF-R and variants thereof.
THOMPSON JEFFREY
HSU YEN-MING
WEN DINGYI
SUN YAPING
Natsuki Morishita